NCT02711202 2026-04-13
Sequential Targeting of Cluster of Differentiation 52 (CD52) and Tumor Necrosis Factor (TNF) Allows Early Minimization Therapy in Kidney Transplantation
Institute for Clinical and Experimental Medicine
Phase NA Completed
Clinical Trials
11 trialsNCT00578292 2020-05-01
THALLO
Baylor College of Medicine
Phase NA Terminated
NCT00038883 2018-11-07
Campath-1H and Allogeneic Blood Stem Cell Transplantation for Lymphoid Malignancies
M.D. Anderson Cancer Center
Phase NA Terminated
NCT00578539 2016-04-22
REGALE
Baylor College of Medicine
Phase NA Terminated
NCT00587847 2015-10-15
Campath Maintenance in Chronic Lymphocytic Leukemia
Northwell Health
Phase NA Terminated
NCT00073879 2015-01-29
Fludarabine, Cyclophosphamide, and Alemtuzumab in Treating Patients With Recurrent or Metastatic Renal Cell Carcinoma (Kidney Cancer) Undergoing Allogeneic Stem Cell Transplantation
Baylor College of Medicine
Phase NA Completed
NCT00021151 2014-01-09
Compassionate Use of Campath-1H in Treating Patients With Refractory Prolymphocytic Leukemia or Chronic Lymphocytic Leukemia
Case Comprehensive Cancer Center
Phase NA Completed
NCT00525876 2011-12-07
Non-Myeloablative Allogeneic Stem Cell Transplantation
M.D. Anderson Cancer Center
Phase NA Completed
NCT00038844 2011-11-02
Safety and Efficacy of Campath in Nonmyeloablative Transplantation
M.D. Anderson Cancer Center
Phase NA Completed
NCT00582894 2011-04-22
Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Malignant Hematological Diseases
University of Oklahoma
Phase NA Completed
NCT00336206 2006-07-25
Low Dose Alemtuzumab for Consolidation and Maintenance of Patients With B-Cell Chronic Lymphocytic Leukemia
Tawam Hospital
Phase NA Unknown